Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Alzheimer's Disease

Interventions

DRUG

Bryostatin 1

25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.

DRUG

Placebo

Placebo, single dose via intravenous infusion over 1 hour.

Trial Locations (1)

California Clinical Trials Medical Center, Glendale